

Financial Tearsheet

Company Overview

SANUWAVE Health, Inc. is an emerging regenerative medicine company focused on the development and commercialization of noninvasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE's portfolio of products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration.

Recent Financial News

Date	Headline
Oct 20, 2021	SANUWAVE Health to Host Conference Call and Provide Business Update
Sep 28, 2021	SANUWAVE Health Provides Business Update
Jul 29, 2021	SANUWAVE Announces Collaboration with NASA for the Mitigation of Bacterial Biofilms Formed in the Water Processor Assembly used on International Space Station (ISS) and for Future Moon Base and Mars Colony
Jul 13, 2021	SANUWAVE Health Provides Updated Conference Call Information
Jul 08, 2021	SANUWAVE Health To Host Conference Call and Provide Business Update

IR Contacts

INVESTOR RELATIONS	TRANSFER AGENT
Lisa Sundstrom Chief Financial Officer T: 678-578-0103 investorrelations@sanuwave.com	Action Stock Transfer Corporation 2469 E. Fort Union Blvd. Suite 214 Salt Lake City, UT 84121 T: 801-274-1088 F: 801-274-1099 info@actionstocktransfer.com
AUDITOR	LEGAL COUNSEL
BDO USA, LLP	Smith, Gambrell & Russell, LLP
INVESTOR RELATIONS	
Christopher Wynne Millennium Park Capital LLC T: 312-724-7845 cwynne@mparkcm.com	











Stock Performance

Stock Fundamentals	Value
Today's Open	0.1200
Volume	40
Day Range	0.1200 - 0.1200
52 Week Range	0.0001 - 0.2400
Bid/Ask	0.0000 / 0.0000
Bid/Ask Size	0 X 0

Previous Close	0.1200
Market Cap	7.57 million
Shares Outstanding	63.06 million
Dividend/Yield	0.0000 / 0.0000%
EPS (TTM)	-0.076217
P/E Ratio (TTM)	N/A

11/19/2021 11:13 AM ET	
Symbol	SNWV
Last Trade	\$0.12
Change (%)	↑ 0 (0.00%)
Volume	40
Quotes delayed at least 20 mins.	

Recent XBRL Filings

Filing Date ▼	Form Type	Description	View
Jul 01, 2021	10-Q/A	Quarterly report (Amendment)	 
Nov 23, 2020	10-Q	Quarterly report	 
Aug 14, 2020	10-Q	Quarterly report	 
May 15, 2020	10-Q	Quarterly report	 
Mar 30, 2020	10-K	Annual report	 

Management Team

Kevin A. Richardson, Chairman and Chief Executive Officer

Shri Parikh, President

Lisa Sundstrom, Chief Financial Officer

Peter Stegagno, Chief Operating Officer

Iulian Cioanta, PhD, Chief Technology and Science Officer

Leon Lambry, Director, Quality and Regulatory Affairs

Board of Directors

Kevin A. Richardson, Chairman and Chief Executive Officer

John F. Nemelka, Director

Alan L. Rubino, Director

A. Michael Stolarski, Director

Dr. Maj-Britt Kaltoft, Director
